Company intelligence / Profile preview

Syndax Pharmaceuticals

Waltham, Massachusetts, United Statessyndax.com ↗

Ownership: Public · SNDX
Employees: ~270
Development stage: Commercial

Overview

Syndax Pharmaceuticals has transitioned to a commercial-stage biopharma with two FDA-approved products:

Revuforj® (revumenib): an oral menin inhibitor for relapsed/refractory acute leukemia with KMT2A rearrangement or NPM1 mutation. Positive pivotal Phase II data in R/R mutant NPM1 AML was announced in late 2024. sNDA filing expected in first half of 2025 based on these results.
Niktimvo™ (axatilimab-csfr): an anti-CSF1R monoclonal antibody approved for chronic graft-versus-host disease. Additional studies are ongoing for earlier lines of cGVHD therapy and idiopathic pulmonary fibrosis. The company continues to expand its pipeline into additional indications and combinations.[9][2][5]

Therapeutic areas: OncologyImmunologyPulmonology
Modalities: Small molecules (menin inhibitors)Monoclonal antibodies (anti-CSF1R mAb)
Industry: Biotech

Drug pipeline

5 assets

revumenib

Approved

4 more assets in the full pipeline.

Request access →

Partnerships

Incyte Corporation – U.S. commercialization partnership for axatilimab/Niktimvo™[2].Eddingpharm International – licensing agreement for entinostat in China[3].UCB – exclusive worldwide license agreement for anti-CSF1R antibody program [7].

Financials

Market cap: $1.7B
Total revenue: $72.8M
Enterprise value: $1.7B

Beyond the preview

Go deeper on Syndax Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Syndax Pharmaceuticals.

Explore the full profile